Summary
The effects of the HMG CoA reductase inhibitors lovastatin and pravastatin on serum lipids, lipoproteins and apolipoproteins have been studied in 35 patients with primary hypercholesterolaemia.
LDL cholesterol was lowered to the same extent by both agents compared on a mg basis of each drug per day. HDL cholesterol was increased by lovastatin but not by pravastatin. The reduction in serum triglycerides, VLDL triglycerides and VLDL cholesterol was more pronounced after lovastatin than pravastatin. After 1 year the effect of combined treatment with 40 mg pravastatin and 8 g cholestyramine on the reduction in LDL cholesterol (−39%) in 13 patients was comparable to that of 80 mg lovastatin plus 8 g cholestyramine (−40%) in 12 patients with identical baseline values.
Differences were also found in the effects of the combination therapy with the two drugs on HDL cholesterol, serum triglycerides, VLDL triglycerides, VLDL cholesterol, and apolipoproteins.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kannel WB, Castelli WP, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90: 85–91
Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986) Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet II: 933–936
Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245
Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374
Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE, et al. (1987) Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med 107: 609–615
Ma PT, Gil G, Sudhof TC, Bilheimer DW, Goldstein JL, Brown MS (1986) Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 83: 8370–8374
Leren TP, Hjermann I, Berg K, Leren P, Foss OP, Viksmoen L (1988) Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 73: 135–141
Hoeg JM, Maher MB, Zech LA, Bailey KR, Gregg RE, Lackner KJ, Fojo SS, Anchors MA, Bojanovski M, Sprecher DL, et al. (1986) Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am J Cardiol 57: 933–939
The Lovastatin Study Group II (1986) Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA 256: 2829–2834
The Lovastatin Study Group III (1988) A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 260: 359–366
Mol MJTM, Erkelens DW, Leuven JA, Schouten JA, Stalenhoef AF (1986) Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet II: 936–939
Leclercq V, Harvengt C (1989) Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial. Int J Clin Pharmacol Ther Toxicol 27: 76–81
Nakaya N, Homma Y, Tamachi H, Shigematsu H, Hata Y, Goto Y (1987) The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA 257: 3088–3093
Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Takeuchi I, et al. (1988) Dose-dependent hypolipidemic effect of an inhibitor of HMG CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis 72: 205–211
Saxenhofer H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, Noseda G (1990) Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II. Eur J Clin Pharmacol 39: 101–105
Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, Margolis S, Dobs AS, Mellies MJ, Insull W Jr, et al. (1990) Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study. Atherosclerosis 85: 81–89
Owens D, Collins P, Johnson A, Tighe O, Robinson K, Tomkin GH (1991) Hypercholesterolaemia: simvastatin and pravastatin alter cholesterol metabolism by different mechanisms. Biochim Biophys Acta 1082: 303–309
Illingworth DR (1989) New horizons in combination drug therapy for hypercholesterolemia. Cardiology 76 [Suppl 1]: 83–94
Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319: 24–33
Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL, Willard AK (1986) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J Med Chem 29: 849–852
Germershausen JI, Hunt VM, Bostedor RG, Bailey PJ, Karkas JD, Alberts AW (1989) Tissue selectivity of the cholesterol lowering agents lovastatin, simvastatin, and pravastatin in rats in vivo. Biochem Biophys Res Commun 158: 667–675
Sachs L (1974) Angewandte Statistik. Springer, Berlin Heidelberg New York
Illingworth DR (1987) Long term administration of lovastatin in the treatment of hypercholesterolaemia. Eur Heart J 8: 103–111
Tobert JA (1988) Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62: 28J-34J
Bilheimer DW (1990) Long-term clinical tolerance of lovastatin and simvastatin. Cardiology 77 [Suppl 4]: 58–65
Yoshino G, Kazumi T, Iwai M, Matsushita M, Matsuba K, Uenoyama R, Iwatani I, Baba S (1989) Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 75: 67–72
Nozaki S, Vega GL, Haddox RJ, Dolan ET, Grundy SM (1990) Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis 84: 101–110
Grundy SM, Vega GL (1985) Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 26: 1464–1475
Mabuchi H, Kamon N, Fujita H, Michishita I, Takeda M, Kajinami K, Itoh H, Wakasugi T, Takeda R (1987) Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Metabolism 36: 475–479
Hoogerbrugge N, Mol MJTM, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef AF, Birkenhager JC (1990) The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. J Intern Med 228: 261–266
Kazumi T, Yoshino G, Kasama T, Iwatani I, Iwai M, Morita S, Baba S (1986) Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia. Horm Metab Res 18: 654–655
Yoshino G, Kazumi T, Iwai M, Iwatani I, Matsuba K, Kasama T, Matsushita M, Otsuki M, Baba S (1988) Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects. Atherosclerosis 71: 95–101
Brown MS, Kovanen PT, Goldstein JL (1981) Regulation of plasma cholesterol by lipoprotein receptors. Science 212: 628–635
Breslow JL (1985) Human apolipoprotein molecular biology and genetic variation. Ann Rev Biochem 54: 699–727
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jacob, B.G., Möhrle, W., Richter, W.O. et al. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia. Eur J Clin Pharmacol 42, 353–358 (1992). https://doi.org/10.1007/BF00280117
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280117